Skip to main content

Structural evidence of differential forms of nanosponges of beta-cyclodextrin and its effect on solubilization of a model drug


Nanosponges (NS) are a recently developed class of hyper-branched polymers, nano-structured to form three dimensional meshwork; obtained by reacting cyclodextrins with a cross linker like diphenyl carbonate. Herein, we report an anomalous behavior of NS with regards to physical and morphological characteristics and drug encapsulation behavior by minor synthetic modification. Two distinct forms viz. crystalline and para-crystalline of NS were identified and extensively characterized by use of high resolution transmission electron microscopy (HR-TEM), X-ray powder diffraction (XRPD), scanning electron microscope, atomic force microscope, optical microscope and Fourier transform infra-red attenuated total reflectance spectroscopy (FTIR-ATR). Dimension of the crystal lattice was found to be equal to 0.61 nm. Higher magnifications clearly showed a zone axis with a hexagonal symmetry as that of beta-cyclodextrin. XRPD patterns were in concurrence with the HR-TEM results. Solubility studies with a model drug dexamethasone (DEX) showed more than three folds increase in the solubility of the drug in the crystalline NS as compared to the para-crystalline ones. Percent drug association and drug loading for DEX was found to be higher in the crystalline type of NS. An In vitro drug kinetic study evidenced a faster release of DEX from the crystalline type NS. The particle sizes of the formulations were as follows: crystalline NS: 688.6 ± 38.0 nm, para-crystalline NS: 702.2 ± 21.2 nm with polydispersity indices of 0.155 and 0.132; zeta-potential of −26.55 ± 1.7 and −23.42 ± 2.1 respectively. Differential scanning calorimetry and thermogravimetric analysis revealed that both forms encapsulated the drug satisfactorily. FTIR-ATR and Raman spectroscopy showed weak interactions. Crystallinity of NS was thus found to be an important factor in solubilization, in vitro kinetics and encapsulation behavior and can be tuned to give a tailored drug release profile or formulation characteristics.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13
Fig. 14


  1. Trotta, F., and Tumiatti, W.: WO 03/085002 (2003)

  2. Swaminathan, S.: Studies on novel dosage forms. Masters of pharmaceutical Sciences Dissertation submitted to the University of Mumbai (2006)

  3. Trotta, F., Cavalli, R.: Characterization and applications of new hyper-cross-linked cyclodextrins. Compos. Interfaces 16, 39–48 (2009)

    Article  CAS  Google Scholar 

  4. Swaminathan, S.: Design and characterization of novel polymeric drug delivery system. Ph.D. (Tech.) Dissertation submitted to the University of Mumbai (2010c)

  5. Cavalli, R., Trotta, F., Tumiatti, W.: Cyclodextrin-based nanosponges for drug delivery. J. Inclusion Phenom. Macrocycl. Chem. 56, 209–213 (2006)

    Article  CAS  Google Scholar 

  6. Swaminathan, S., Vavia, P.R., Trotta, F., Torne, S.J.: Formulation of betacyclodextrin based nanosponges of itraconazole. J. Inclusion Phenom. Macrocycl. Chem. 57, 89–94 (2007)

    Article  CAS  Google Scholar 

  7. Swaminathan, S., et al.: Novel functionalized beta cyclodextrin nanosponge based stable formulation of camptothecin and in vitro cytotoxicity evaluation. A poster presented at the Fifth Asian cyclodextrin conference in Busan, Korea (2009)

  8. Swaminathan, S., et al.: Cyclodextrin-based nanosponges encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity. Eur. J. Pharm. Biopharm. 74, 193–201 (2010)

    Article  CAS  Google Scholar 

  9. Swaminathan, S., et al.: In vitro release modulation and conformational stabilization of a model protein using swellable polyamidoamine nanosponges of β-cylcodextrin. J. Inclusion Phenom. Macrocycl. Chem. 68(1–2), 183–191 (2010)

    Article  CAS  Google Scholar 

  10. Vavia, P.R., et al.: Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. Drug Deliv. 17(6), 419–425 (2010)

    Article  Google Scholar 

  11. Vavia, P.R., et al.: Paclitaxel loaded nanosponges: in vitro characterization and cytotoxicity study on MCF-7 cell line culture. Curr. Drug Deliv. 8(2), 194–202 (2011)

    Article  Google Scholar 

  12. Ansari, K.A., Vavia, P.R., Trotta, F., Cavalli, R.: Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterization, stability, cytotoxicity and permeation study. AAPS Pharmsci. Tech. 12(1), 279–286 (2010)

    Article  Google Scholar 

  13. Vavia, P.R., Swaminathan, S., Trotta, F., and Cavalli, R.: Applications of nanosponges in drug delivery, XIII international cyclodextrin symposium, Turin (2006)

  14. Andrea, M., et al.: HR MAS NMR, powder XRD and Raman spectroscopy study of inclusion phenomenon in β CD nanosponges. J. Inclusion Phenom. Macrocycl. Chem. 69(3–4), 403–409 (2010)

    Google Scholar 

  15. Kim, J., Chauhan, A.: Dexamethasone transport and ocular delivery from poly(hydroxyethyl methacrylate) gels. Int. J. Pharm. 353, 205–222 (2008)

    CAS  Google Scholar 

  16. Clark, A.F., Yorio, T.: Ophthalmic drug discovery. Nat. Rev. Drug Discov. 2, 448–459 (2003)

    Article  CAS  Google Scholar 

  17. Melby, J.C.: Drug spotlight program: systemic corticosteroid therapy: pharmacology and endocrinologic considerations. Ann. Intern. Med. 81, 505–512 (1974)

    Article  CAS  Google Scholar 

  18. Schwartz, B.: The response of ocular pressure to corticosteroids. Int. Ophthalmol. Clin. 6, 929–989 (1966)

    Article  CAS  Google Scholar 

  19. Urban, R.C., Cotlier, E.: Corticosteroid-induced cataracts. Surv. Ophthalmol. 31, 102–110 (1986)

    Article  CAS  Google Scholar 

  20. Li, C.C., Chauhan, A.: Modeling ophthalmic drug delivery by soaked contact lenses. Ind. Eng. Chem. Res. 45, 3718–3734 (2006)

    Article  CAS  Google Scholar 

  21. Ferrante, P., Ramsey, A., Bunce, C., Lightman, S.: Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin. Exp. Ophthalmol. 32, 563–568 (2004)

    Article  Google Scholar 

  22. Young, S., Larkin, G., Branley, M., Lightman, S.: Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin. Exp. Ophthalmol. 29, 2–6 (2001)

    Article  CAS  Google Scholar 

  23. Kwak, H.W., D’Amico, D.J.: Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch. Ophthalmol. 110, 259–266 (1992)

    Article  CAS  Google Scholar 

  24. Torne, S.J.: Studies on novel dosage form. Ph.D. (Tech.) Dissertation submitted to the University of Mumbai, India (2007)

Download references


The authors would like to acknowledge Prof. Aquilano and Dr. Linda Pastero for their help in X-ray studies. The authors are thankful to M/s Sea Marconi Inc. Colegno, Italy, All India Council of Technical Education and National Facilities in Engineering and Technology with Industrial Collaboration for the funding and facilities respectively.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Pradeep R. Vavia.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Swaminathan, S., Vavia, P.R., Trotta, F. et al. Structural evidence of differential forms of nanosponges of beta-cyclodextrin and its effect on solubilization of a model drug. J Incl Phenom Macrocycl Chem 76, 201–211 (2013).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Beta cyclodextrin
  • Nanosponge
  • Inclusion complexation
  • Dexamethasone
  • Solubilization